Data from: Assessment of the broader economic consequences of HPV prevention from a government-perspective: a fiscal analytic approach

Background. Cervical cancer poses a substantial burden in terms of
morbidity, mortality, and economic losses, especially in low/middle-income
countries. HPV vaccination and/or cervical cancer screening among females
may reduce the burden of HPV-related diseases, including cervical cancer.
However, limited funds may impede the implementation of population-based
programmes. Governmental investments in the prevention of infectious
disease may have broader economic and fiscal benefits, which are not
accounted in conventional economic analyses. This study estimates the
broader economic and fiscal impacts of implementing HPV vaccination and/or
cervical cancer screening in Indonesia from the perspective of the
government. Methods. A government-perspective quantitative analytic
framework was applied to assess the Net Present Value (NPV) of investment
on cervical cancer prevention strategies including HPV vaccination,
cervical screening and its combination in Indonesia. All monetary values
were presented in International Dollars (I$). Results. Based on a cohort
of 10,000,000 Indonesian 12-year-old females, it was estimated that HPV
vaccination and/or cervical cancer screening result in a positive NPV for
the Indonesian government. The combination of cervical screening and HPV
vaccination generated a substantial reduction of cervical cancer incidence
and HPV-related mortality of 87,862 and 19,359, respectively. It was
estimated that HPV vaccination in combination with cervical screening is
the most favorable option for cervical cancer prevention (NPV
I$2.031.786.000), followed by HPV vaccination alone (NPV I$1.860.783.000)
and cervical screening alone (NPV I$375.244.000). Conclusion. In addition
to clinical benefits, investing in HPV vaccination and cervical screening
may yield considerable fiscal benefits for the Indonesian governments due
to lifelong benefits resulting from reduction of cervical cancer-related
morbidity and mortality.